Diabetic nephropathy

被引：0

作者：

Zukowska-Szczechowska, Ewa ^{[1
]}

Wystrychowski, Grzegorz ^{[1
]}

机构：

[1] Slaskiego Uniwersytetu Med Katowicach, Katedra Klin Chorob Wewnetrznych Diabetol & Nefro, Katowice, Poland

来源：

FAMILY MEDICINE AND PRIMARY CARE REVIEW | 2008年 / 10卷 / 03期

关键词：

diabetic nephropathy; microalbuminuria; cardiovascular risk;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Diabetic nephropathy affects 20-40% of type 1 or 2 diabetic patients. Beside progressive renal damage leading to end stage renal disease, diabetic nephropathy augments the risk of cardiovascular complications in the course of diabetes, being a marker of a generalized macroangiopathy. Essential for prevention and treatment of vascular complications in diabetes remains elimination of the risk factors of diabetic nephropathy -control of glycemia, blood pressure, and correction of dyslipidemia. A significant role is played by the blockade of the rennin- angiotensin system. New drugs of such a mechanism of action, as well as new therapeutic options of protection from microangiopathy on the cellular level, shall allow for a more efficient fight against diabetic nephropathy at the beginning of 21st century.

引用

收藏

页码：1191 / 1196

页数：6

相关论文

共 39 条

[1] Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats [J].

Adamczak, M ;

Gross, ML ;

Krtil, J ;

Koch, A ;

Tyralla, K ;

Amann, K ;

Ritz, E .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (11) :2833-2842

[2] Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].

Adler, AI ;

Stevens, RJ ;

Manley, SE ;

Bilous, RW ;

Cull, CA ;

Holman, RR .

KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232

[3] Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels [J].

Agarwal, R ;

Siva, S ;

Dunn, SR ;

Sharma, K .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (03) :486-492

[4] Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects [J].

Ahmad, J ;

Shafique, S ;

Abidi, SMA ;

Parwez, I .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 60 (02) :131-138

[5] THE EFFECT OF ENALAPRIL ON GLOMERULAR GROWTH AND GLOMERULAR-LESIONS AFTER SUBTOTAL NEPHRECTOMY IN THE RAT - A STEREOLOGICAL ANALYSIS [J].

AMANN, K ;

IRZYNIEC, T ;

MALL, G ;

RITZ, E .

JOURNAL OF HYPERTENSION, 1993, 11 (09) :969-975

[6] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[7] Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data [J].

Chaturvedi, N .

ANNALS OF INTERNAL MEDICINE, 2001, 134 (05) :370-379

[8] Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold [J].

Chaturvedi, N ;

Bandinelli, S ;

Mangili, R ;

Penno, G ;

Rottiers, RE ;

Fuller, JH .

KIDNEY INTERNATIONAL, 2001, 60 (01) :219-227

[9] Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes [J].

Epstein, Murray ;

Williams, Gordon H. ;

Weinberger, Myron ;

Lewin, Andrew ;

Krause, Scott ;

Mukherjee, Robin ;

Patni, Rajiv ;

Beckerman, Bruce .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (05) :940-951

[10] Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999 [J].

Foley, RN ;

Murray, AM ;

Li, SL ;

Herzog, CA ;

McBean, AM ;

Eggers, PW ;

Collins, AJ .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (02) :489-495

← 1 2 3 4 →